MannKind Corp

MannKind Corporation has entered into a securities purchase agreement for a private placement expected to generate approximately $50 million in gross proceeds. The financing was led by Frazier Life Sciences, a longstanding biotech investment firm. MannKind is selling 10,440,838 shares of common stock and pre-funded warrants to purchase up to 2,412,632 shares, priced at $3.89 per share and $3.88 per pre-funded warrant. The company intends to use the net proceeds for general corporate purposes, including funding a $45 million contingent value rights payment triggered by the recent FDA approval of Furoscix ReadyFlow. The closing is expected on or about July 24, 2026, subject to customary conditions.

MannKind Corporation EVP General Counsel & Secretary David Thomson sold 123,000 shares of common stock between July 15 and July 17, 2026, at a weighted average price of $4.08 per share, totaling about $500,000. The majority of the disposition, 98,426 shares, was a non-discretionary withholding by the company to cover tax liabilities from the vesting of performance-based restricted stock units that paid out at 83% of target after MannKind's total shareholder return ranked at the 41.5th percentile of the Russell 3000 Pharmaceutical & Biotechnology Index over a three-year period ending June 30, 2026. The remaining 24,109 shares were sold under a Rule 10b5-1 trading plan established on December 2, 2025. Following the transactions, Thomson directly holds nearly 798,000 shares valued at $3.21 million based on the July 17, 2026 close. The filing comes as MannKind faces uncertainty over its Tyvaso DPI royalty stream, which generated $32.7 million in the first quarter, after United Therapeutics launched a competing inhaler called Tresmi.

A MannKind insider sold 65,808 shares for about $269,000, but the transaction was a non-discretionary disposition to cover tax withholding obligations, not a voluntary market sale. The shares came from a May 2023 performance-based award that vested at 83% of target after the company met stock-price and total-shareholder-return goals relative to the Russell 3000 Pharmaceutical & Biotechnology Index. Following the sale, Chief People & Workplace Officer Stuart A. Tross still directly holds roughly 1.1 million shares. More significant for investors is the risk to MannKind's 9% royalty on Tyvaso DPI, which generated $32.7 million in the first quarter, after United Therapeutics unveiled a competing soft-mist inhaler called Tresmi that its CEO labeled a category killer.

MannKind Corporation CEO Michael Castagna disposed of 363,200 shares on July 15, 2026, in a non-discretionary transaction to satisfy tax withholding obligations tied to the vesting of restricted stock units. The sale, valued at approximately $1.5 million based on a weighted average price of $4.09 per share, represented 13% of his direct equity holdings. Following the transaction, Castagna retains 2,433,779 shares directly, maintaining significant exposure to the company's long-term performance. The underlying RSUs vested after MannKind achieved 83% of performance targets linked to total shareholder return and stock price benchmarks set in May 2023.